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Abstract
We have developed an enhanced form of reduced representation bisulfite sequencing with extended genomic coverage,
which resulted in greater capture of DNA methylation information of regions lying outside of traditional CpG islands.
Applying this method to primary human bone marrow specimens from patients with Acute Myelogeneous Leukemia (AML),
we demonstrated that genetically distinct AML subtypes display diametrically opposed DNA methylation patterns. As
compared to normal controls, we observed widespread hypermethylation in IDH mutant AMLs, preferentially targeting
promoter regions and CpG islands neighboring the transcription start sites of genes. In contrast, AMLs harboring
translocations affecting the MLL gene displayed extensive loss of methylation of an almost mutually exclusive set of CpGs,
which instead affected introns and distal intergenic CpG islands and shores. When analyzed in conjunction with gene
expression profiles, it became apparent that these specific patterns of DNA methylation result in differing roles in gene
expression regulation. However, despite this subtype-specific DNA methylation patterning, a much smaller set of CpG sites
are consistently affected in both AML subtypes. Most CpG sites in this common core of aberrantly methylated CpGs were
hypermethylated in both AML subtypes. Therefore, aberrant DNA methylation patterns in AML do not occur in a
stereotypical manner but rather are highly specific and associated with specific driving genetic lesions.
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Introduction
Acute myeloid leukemia (AML) is considered to be a genetically
heterogeneous group of diseases, featuring functionally distinct
somatic mutations and chromosomal translocations [1]. Many of
these mutations involve aberrant transcriptional and epigenetic
regulators, such as translocations involving chromosome 11q23,
which fuse the N-terminal portion of the Mixed Lineage Leukemia
protein (MLL) to various fusion partners. MLL fusion proteins
feature aberrant chromatin modifying functions and drive
leukemogenesis through aberrant transcriptional activation of
target genes such as HOXA9 [2–4]. More recently, AML
associated heterozygous somatic mutations of isocitrate dehydro-
genase 1 or 2 (IDH1 or 2) were shown to result in a gain of
function enzyme that uses alpha-ketoglutarate (aKG) as a
substrate to generate the oncometabolite 2-hydroxyglutarate
(2HG) [5]. Accumulation of 2HG inhibits the function of aKG-
dependent enzymes including the TET family of dioxygenases [6–
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8]. TET proteins contribute to DNA demethylation by hydrox-
ylating 5-methylcytosine (5mC) [9]. 2HG-induced suppression of
TET proteins leads to accumulation of DNA methylation with
effects on epigenetic gene regulation [10].
DNA methylation profiling of AMLs indicate that disruption of
promoter cytosine methylation patterning is a universal feature of
the disease. Promoter methylation signatures identify AML as
composed of sixteen epigenetically defined subtypes [11]. One of
these epigenetically defined AML subtypes feature 11q23 trans-
locations and another features IDH1/2 somatic mutations.
Indeed, abnormal promoter methylation has been noted in several
other cancers. Recent more comprehensive DNA methylation
sequencing studies indicate that cancers display perturbed cytosine
methylation compared to normal tissues either on the basis of
changes in CpG island methylation or alternatively at CpG shores,
and have offered partially different visions of how DNA
methylation is perturbed in tumor cells, in part influenced by
technical differences in methods used to capture this information
[12–14]. However, direct and quantitative genome scale studies of
cytosine methylation perturbation in the context of tumors with
specific genetic backgrounds have not been published for any
cancer. Hence it is not known whether epigenetic patterning in
cancer has a stereotypical pattern with a subtext of certain
promoter specific aberrancies, or whether epigenetic patterning is
mechanism and tumor subtype specific. One practical way to
approach this question is through reduced representation bisulfite
sequencing (RRBS), an efficient method for quantitative, base-pair
resolution of cytosine methylation across the genome [15,16].
However, this procedure has been shown to mainly represent CpG
islands at the expense of other genomic regions [17,18]. In order
to address the question of whether DNA methylation patterning is
stereotyped or mechanism specific in tumors, we established an
enhanced RRBS procedure (ERRBS) that provides biochemical
and bioinformatic methodological improvements that generate
more extensive and balanced coverage of CpGs. ERRBS analysis
of normal hematopoietic stem cells in comparison with MLL
rearranged (MLLr) or IDH1/2 mutant (IDH-mut) AMLs reveals
that DNA methylation patterning is established in a profoundly
distinct and mechanism specific manner in AMLs.
Results
Expansion of RRBS for enhanced coverage of genomic
CpG methylation
We sought to examine quantitative, base-pair resolution DNA
methylation patterns in clinical specimens with limited cell
numbers, with adequate coverage of CpGs both within and
outside of CpG islands. To accomplish this, we developed a
modified version of the RRBS protocol, which retains its
quantitative base-pair resolution while improving the coverage of
regions outside CpG islands. We first validated the performance of
the original RRBS assay using genomic DNA extracted from the
HCT116 colon cancer cell line. We observed that RRBS yielded
robust and reproducible results over a wide range of starting
material ranging from 5 ng to 1000 ng (Figure S1A) without any
significant sequencing strand bias (Figure S1B).
We next modified RRBS into a format that would be practical
to perform in limited clinical specimens. First, we eliminated an
intermediate clean-up procedure between the two rounds of
bisulfite treatment in order to minimize sample loss during library
preparation. Instead of two rounds of bisulfite conversion as
previously described [16,19] we used just one 16-hour round using
the EZ DNA Methylation Kit (Zymo Research, CA) with slight
modifications to the manufacturer’s suggested protocol (see
methods section). This approach routinely achieves a conversion
rate greater than 99.8% in both human and murine samples
(Table S1). Conversion rates .99% with RRBS have been
observed but not consistently achieved and rarely surpass 99.5%,
even with repeated rounds of bisulfite conversion [16].
While RRBS has been shown to reliably detect gain of
methylation, its ability to accurately detect genome-wide loss of
methylation has not been extensively probed. Yet this is essential
for clinical samples, since aberrant hypomethylation can be a
dominant feature of tumor cells [7,11,12,20]. Furthermore, DNA
methyltransferase (DNMT) inhibitor drugs currently used in the
clinic are capable of inducing extensive hypomethylation [21]. In
order to examine the dynamic range of the RRBS, we compared
and contrasted the methylomes of HCT116 cells and the related
cell line HCT116-DKO clone 2 (DKO2) which lacks DNMT1
and DNMT3b [22]. DNA methylation in HCT116 showed the
expected bimodal distribution, with the vast majority of CpG sites
in the 0–10% and 90–100% methylation range (Figure S1B). In
contrast, the DKO2 cell line had a unimodal peak containing
.83% of the reads with levels of methylation of 0–10%. Only
5.5% of DKO reads displayed .50% methylation. (Figure S1C).
Even under these extreme hypomethylated conditions the
modified bisulfite treatment protocol continued to perform
robustly (conversion rate = 99.9%). We further validated the
accuracy of the ERRBS assay with MassArray Epityping at 45
individual CpG sites, showing an extremely high degree of
correlation (r = 0.97) (Figure S1D).
An increasing body of evidence demonstrates that biologically
relevant changes in DNA methylation in cancer occur beyond
CpG islands [12,13,23]. Because RRBS only interrogates CpGs
within short MspI delimited fragments between 40 to 220 bp, it is
inherently biased towards representing CpG islands, which
typically contain more densely clustered MspI sites [17,18]. In
order to enhance the capture of regions beyond CpG islands, MspI
fragments ranging from 70–320 bp were selected instead. This
enhanced RRBS (ERRBS) method yielded a 75% increase in
coverage of CpG sites with a 54% increase in coverage of CpG
shores (defined as 2000 bp flanks on upstream and downstream of
CpG islands). We also observed a 58% increase in the number of
introns captured vs. RRBS, a 54% increase in the number of
exons and an 11.9% increase in the number of promoter regions
(Figure 1A and 1B).
While the original RRBS alignment strategy used an MspI
fragmented genome as a reference, whole-genome alignment
strategies can also be applied to these data [18]. In a direct
comparison of both strategies, we observed that a whole-genome
Author Summary
Acute myeloid leukemias (AML) are a group of malignan-
cies that originate in the bone marrow. While many
different genetic lesions have been linked to the different
forms of this disease, it is also clear that these genetic
lesions are not always sufficient to cause AML. DNA
methylation plays a role in gene expression regulation, and
abnormal distribution of DNA methylation has been
observed in many cancers, including AML. Here we
demonstrate that changes in DNA methylation in AML
are not uniform across all AML subtypes, but rather they
display unique patterns, which are closely linked to the
underlying genetic lesions of each of the different forms of
AML. Furthermore, these unique patterns of DNA methyl-
ation have different impacts on gene expression regula-
tion in each AML subtype.
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alignment approach using the Bowtie aligner via the Bismark
software [24] more than doubled the number of aligned reads
which resulted in an increased recovery of the number of CpGs
(mean increase 200,154+/2135,012) (Figure 1C). Eliminating the
use of an MspI site as the absolute alignment requirement at the
beginning of reads, as well as the use of a longer (32 bp) seed
length, further improved accuracy by excluding those reads that
had the potential for more than one unique match or mismatch
(Figure 1D). Theoretically, no reads should map to regions of the
genome that are not flanked by an MspI restriction sites, yet we
found that on average 29% of the aligned reads mapped to non-
MspI fragments. These fragments, which would be discarded
when using in silico digested genomes for alignment, were likely
produced due to either restriction enzyme non-specific activity, the
presence of partially degraded DNA at the onset of the protocol, or
variations in the patient genome compared to the reference
genome. Collectively these approaches enhanced not only
genomic coverage, but also alignment efficiency and accuracy.
Tumor subtype–specific DNA methylation patterns
extend beyond promoter regions
We previously reported that IDH-mut and MLLr AMLs
distribute to different DNA methylation clusters and have distinct
promoter DNA methylation signatures compared to normal
CD34+ bone marrow controls (NBM) [10,11]. We performed
ERRBS in two IDH-mut AML samples, two MLLr cases
harboring t(9;11)(q22,q23) translocations, and two NBM samples.
ERRBS covered an average of 2,082,426 CpGs per sample. In
addition to the expected high correlation between the NBMs
(r = 0.96) there was a remarkable degree of correlation between
the two IDH patients (r = 0.93) and the two MLLr patients
(r = 0.92) (Figure S2), which far exceeded the correlation between
MLLr and IDH-mut patients (r = 0.85–0.88), suggesting a strong
link between genetic background and its effects on cytosine
methylation. Unsupervised analyses using hierarchical clustering
(1-Pearson correlation distance + Ward clustering method) and
principal component analysis revealed that, even with this greatly
enhanced representation of the genome, ERRBS methylation
profiles from IDH-mut and MLLr naturally segregate from each
other just as strongly as from NBM (Figure 2A and Figure S3A). In
order to determine whether this natural segregation was driven
solely by promoter differences in methylation, as captured in our
previous studies, or whether biologically relevant differences were
conserved in all genomic regions, we repeated the clustering
analysis using only CpG sites within defined genomic regions. We
found that using either (1) all non-promoter CpGs, (2) non-
Figure 1. ERRBS improves genomic coverage and alignment accuracy. (A) Average CpG number coverage for ERRBS (red) and RRBS (green)
methods (n = 3, samples NBM_#2, AML and MLLr_#1). (B) Average percent coverage of different genomic regions by ERRBS (red) and RRBS (green)
(n = 3, samples NBM_#2, AML and MLLr_#1) (C) Average percentage of uniquely aligned reads using a whole genome reference strategy (black) or
an MspI in silico digested genome reference (gray) (n = 4, samples NBM_#2, AML_Rep#2, MLLr_#1 and MLLr_#2) (D) Example of a misalignment
due to the use of a reduced representation bisulfite converted reference genome. The read aligns to a unique genomic location using the MspI
alignment algorithm (forward strand, chr1: 876391–876441), however the same fragment does not align uniquely when using a whole genome
alignment algorithm, rather it also aligns to the reverse strand of chr 2: 130,704,784–130,704,833.
doi:10.1371/journal.pgen.1002781.g001
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Figure 2. Diametrically opposed DNA methylation patterns in MLLr and IDH-mut AMLs. (A) Unsupervised analysis of DNA methylation by
ERRBS using hierarchical clustering (distance = 1-Pearson correlation, Ward’s agglomeration method) segregates the samples into their three
biological groups using all CpGs. (B) This segregation is maintained when unsupervised analysis is performed on non-promoter CpGs. (C)
Chromosome ideogram representing differential methylation in IDH-mut AMLs vs. NBM (left) and MLLr AMLs vs NBM (right). Only CpGs with q-
value,0.01 and methylation difference of at least 25% are shown. Magenta points represent hypermethylation and green ones represent
hypomethylation relative to NBM. (D) Stacking barplots showing percentage of hyper and hypomethylated DMCs out of all covered CpGs for each
chromosome in IDH-mut AMLs (left) and MLLr AMLs (right). Green represents proportion of hypomethylated DMCs and magenta represents
hypermethylated ones.
doi:10.1371/journal.pgen.1002781.g002
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promoter intron CpGs, or (3) CpG sites at CpG islands and shores
regardless of genomic location, the clustering results still retained
the natural segregation into the biological groups (Figure 2B and
Figure S3B–S3E). Notably, when the clustering was performed on
CpG island-associated CpG sites (Figure S3D), IDH-mut AMLs
segregated further apart from NBMs and MLLr AMLs, indicating
that these sites are likely to be more heavily involved in the
aberrant DNA methylation profiles of these AMLs. These findings
demonstrate the existence of robust AML subtype-specific DNA
methylation patterns, which extend beyond promoters to include
other genomic regions.
Diametrically opposed aberrant DNA methylation in IDH-
mut and MLLr AML subtypes
In order to identify the nature of the differences between IDH-
mut and MLLr AMLs , the cytosine methylation profiles of these
tumors were compared to normal CD34+ bone marrow cells from
healthy donors (NBM), using logistic regression (FDR at
alpha= 0.01). In addition to statistical significance, we required
a minimum cutoff of 25% methylation difference. This analysis
revealed striking differences in the way that these two forms of
AML differed from normal hematopoietic stem and progenitor
cells. Specifically, we observed that IDH-mut AMLs display
profound hypermethylation distributed across all chromosomes. In
marked contrast, comparison of the cytosine methylation profiles
of MLLr AMLs to NBM samples identified a predominance of
aberrantly hypomethylated CpG site (Figure 2C and 2D). More
specifically, we identified 62,367 differentially methylated cytosines
(DMC) between IDH-mut AMLs and NBM, 89.6% of which were
aberrantly hypermethylated in the leukemias and only 10.4%
hypomethylated. Among the 85,216 DMCs identified in MLLr
AMLs we observed a vastly different and opposing distribution
(Chi-square test, p-value,0.0001), with only 28.5% of DMCs
displaying hypermethylation and 71.5% being hypomethylated.
The above results remained valid even when we used a more
stringent cutoff of 40% methylation difference or a more relaxed
cutoff of 10% (Figure S4A and S4B). These results demonstrate
that the directionality of DNA methylation changes acquired
during malignant transformation of myeloid hematopoietic cells is
not uniform across all AML subtypes and that DNA methylation
changes are indeed diametrically opposed in these two AML
subtypes.
Mutually exclusive targeting of aberrant CpG
methylation sites in IDH versus MLL mutant AMLs
Previous studies in AML were restricted to promoter micro-
arrays [11,25] or locus specific assays [25] that do not provide
wide-spread and unbiased base pair resolution. Thus, it is not yet
fully understood how aberrant DNA methylation is distributed in
AML beyond these limited regions. Moreover, it is not clear
whether results from studies carried out on certain solid tumor
specimens [12,13] are generally applicable to cancer, nor whether
genetic background of tumors, and more specifically AML, can
have an influence on what regions are perturbed. The base pair
resolution and extended genomic coverage of ERRBS make it well
suited to address these questions. To compare methylation status
across all samples, we first identified a total of 574,178 CpGs
adequately represented by ERRBS (.106 coverage; on average
536 coverage per base) in all specimens. Of these, 94,245 CpGs
were differentially methylated (methylation difference .25%) in
either one or both subtypes. Notably, 87.3% (n= 82,312) of these
DMCs were non-overlapping and thus unique to either IDH-mut
or MLLr leukemias (Figure 3). More specifically, 51,586 DMCs
were identified in IDH-mut AMLs, of which the majority of CpGs,
or 76.8%, were unique and non-overlapping with MLLr. In the
case of MLLr AMLs, there were 54,592 DMCs, 78% of which
were unique and non-overlapping with IDH-mut cases. Even
more strikingly, 93% of the IDH-mut specific DMCs were
hypermethylated vs. NBM, whereas 80.8% of MLLr specific
DMCs were aberrantly hypomethylated. Comparable results were
observed even when either a more stringent 40% or a less stringent
10% cutoff was used for calling DMCs (Figure S4). Pathway
enrichment analysis of the DMCs observed in each subtype was
performed using GREAT [26]. Only pathways with an FDR q-
value,0.05 in both the hypergeometric and binomial tests were
included. This analysis revealed that IDH-mut DMCs were
enriched in several pathways, including cadherin, Notch and
TGFb signaling (Table S3A). MLLr DMCs on the other hand
featured enrichment of two pathways, one involving integrin
signaling while the other included transcriptional activators
EP300, CREBBP, FOS, JUN as well as several genes involved in
regulation of apoptosis such as BAX, CASP3, CASP6 and TP73
(Table S3B). Hence the DNA methylation defect of these two
AML subtypes is not only perturbed in opposite directions but is
also based on the differential methylation of an almost completely
distinct set of CpGs, which affect distinct pathways.
Since our alignment strategy spanned the entire genome and
used exact matches, we were able to determine whether DMCs
were preferentially associated with certain repetitive sequences in
the genome. Overall, we found that only 15% of CpG sites
covered by ERRBS in all samples overlapped with repeat regions.
However, we found that hypomethylated DMCs were enriched for
repeat elements, with 24% overlap in MLLr (Odds-Ratio: 1.8, p-
value 2.2e-16) and 26% in IDH-mut (Odds-Ratio: 2.0, p-value
2.2e-16), and most of those DMCs were found at Alu elements
(8% in IDH-mut and 10% in MLLr). Hypermethylated DMCs, on
the other hand were depleted for repeat elements, with only 7 and
8% of hypermethylated DMCs overlapping with repeats in IDH-
mut and MLLr, respectively (Odds-Ratio for both 0.4, p-value
2.2e-16). These were, mostly low complexity and simple repeats
(Figure S5).
Next we examined the common differentially methylated CpG
sites in IDH-mut and MLLr AML (n= 11,933). Of these, 76.6%
(n= 9148) were coordinately differentially methylated in the same
direction in both AML subtypes, and the majority of these DMCs
were aberrantly hypermethylated vs. NBMs (79%, n= 7223).
These concordantly hypermethylated DMCs were more frequent-
ly associated with polycomb repressive marks than concordantly
hypomethylated DMCs (66.2% vs. 46.2%, p-value,2.2e-16,
Fisher’s exact test). Concordantly hypermethylated CpGs were
associated with genes involved in Cadherin, Wnt and Notch
signaling pathways, many of which have been previously reported
as frequently methylated in a variety of neoplasms, such as APC2
[27,28], SFRP2 [29], CDH13 [30,31], CDH15 [32] and
PCDH10 [33,34] (see Table S4). However, concordantly hypo-
methylated CpGs were not associated with any pathway but were
instead significantly associated with repeat elements: 27.7% of
concordantly hypomethylated CpGs overlapped with repeats, but
only 7.4% of concordantly hypermethylated CpGs overlapped
with a repeat (Fisher’s exact test p-value,2.2e-16). This degree of
overlap is similar to what we observed in the more global analysis
of repeat elements mentioned above, indicating that concordantly
hypomethylated DMCs are not enriched for repeat elements
compared to subtype-specific DMCs. Hence, although the
majority of DMCs in these two AML subtypes affect different
CpGs in opposite directions there remains a core set of commonly
affected CpGs, which are mostly concordantly hypermethylated
Subtype-Specific DNA Methylation in AML
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Figure 3. Aberrant methylation targets a minimally overlapping set of CpGs in IDH-mut and MLLr AMLs. (A) Venn diagram representing
differentially methylated CpGs identified for IDH-mut and MLLr AMLs from amongst the 574,178 CpGs adequately represented (.106 coverage)
across all six samples. Most DMCs are unique to either AML subtype, with minimal amount of events occurring at common sites across IDH-mut and
Subtype-Specific DNA Methylation in AML
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regardless of genetic background. These results are consistent with
an observation based on HELP assays indicating the frequent
hypermethylation of a core set of 45 genes in AML [11]. Despite
the differences in coverage between ERRBS and the microarray
platform used in our previous studies, we found that 15/18 genes
covered by both assays again presented with aberrant CpG
hypermethylation in both AML subtypes in this current study
(Table S5). Altogether, the data suggest two layers of epigenetic
programming in AML, the first represented by perturbations
specific to tumor subtype, and the second encompassing defects
representative of the leukemic phenotype in general.
Differential deregulation of CpG shores versus CpG
islands according to genetic background
Different types of analyses and platforms used in previous
studies have tended to favor either aberrant methylation of CpG
islands [14,35] or CpG shores [12,13] as the dominant defect in
tumors. However it is not clear whether these observed differences
are dependent on tumor type and/or methodology utilized in the
different studies. The use of the ERRBS platform allowed us to
explore differential methylation of both of these regions simulta-
neously. In order to understand which genomic regions present the
highest variation in leukemias compared to NBM cells, we
calculated differential methylation levels for individual CpG sites
annotated to both CpG islands and shores. Our data revealed that
CpG shores represented the regions with the highest variability in
methylation in the MLLr AMLs (Wilcoxon rank sum test p-value
3.190e-11) (Figure 4B). In contrast, IDH-mut AMLs had higher
variability in DNA methylation at CpG islands than CpG shores
(Wilcoxon rank sum test P- value,2.2e-16).
We also observed significant differences in the absolute numbers
of DMCs distributed to CpG islands and shores between the two
subtypes (Chi-square test, p-value,0.0001). Specifically, we found
that DMCs more frequently mapped to CpG islands in the IDH-
mut AMLs cases (50% in IDH-mut vs. 29% in MLLr). In contrast,
50% of DMCs in the MLLr AMLs were found neither at CpG
islands nor CpG shores but were instead annotated to regions even
beyond CpG shores (Figure 4C). These findings indicate that
distribution of DNA methylation changes during malignant
transformation do not follow a uniform rule across all tumor
types and genetic backgrounds, but rather that specific changes
within and beyond genes are observed with distinct malignancy
driving mechanisms.
Distinct regional distribution of aberrant DNA
methylation in IDH versus MLL AMLs
When considering the relation of DMCs to RefSeq annotated
genes we observed that approximately 40% of all DMCs in both
AML subtypes were found within gene bodies. However, more
detailed analysis identified markedly dissimilar regional distribution
of DMCs between the IDH-mut and MLLr AMLs. First, MLLr
AMLs displayed significantly more abundant DMCs at introns than
IDH-mut AMLs (31 vs. 25%) and intergenic regions (39 vs. 35%). In
contrast, promoter-associated DMCs were twice as frequent in
IDH-mut AMLs (27 vs. 16%) (Figure 5A) (Chi-square test, p-
value,2.2e-16). A similar trend exists if we look at the percentages
of introns, exons and promoters overlapping with a DMC in MLLr
and IDH-mut. In IDH-mut, promoters more frequently overlap
with DMCs whereas in MLLr, introns more frequently overlap with
DMCs. This result demonstrates preferential localization of DMCs
in different samples, where variability of methylation shifts its focus
to different genomic features (Figure 5B). Moreover, the median
upstream distance from the transcription start site (TSS) to observed
DMCs was significantly greater in MLLr AMLs than in IDH-mut
AMLs (11,013 bp vs. 5,737 bp, Wilcoxon rank sum test p-
value,2.2e-16, Figure 5C). These analyses reveal yet another layer
of difference between the two AML subtypes, with IDH-mut AMLs
mainly affecting DNA methylation of CpG island promoter regions
surrounding the TSS whereas MLLr AMLs mainly disrupt
upstream and downstream regions, mostly independent of CpG
islands. When considering promoters according to CpG frequency
(as defined by Weber et al according to CpG ratio, GC content and
length of CpG-rich region [36]), we found that more of the high
CpG promoters (HCPs) overlap with DMCs in both IDH-mut and
MLLr compared to low CpG promoters (LCPs) (17.1% vs 7.9% in
IDH-mut: p-value,2.2e-16 and, 11.1% vs 4.9% in MLLr: p-
value= 9.4e-12). However, it was intermediate CpG promoters
(ICPs) that were the most enriched with DMCs in both leukemia
subtypes: 73% of ICPs in IDH-mut and 71% of ICPs in MLLr with
covered CpGs overlapped with DMCs.
We then examined these regional differences in cytosine
methylation relative to known regulatory elements. We compared
the DMC sites from both IDH-mut and MLLr AMLs to available
ENCODE data sets [37] for CTCF binding and H3K4me1 and
H3K4me3 data to define enhancer sites (defined as sites positive for
H3K4me1 and devoid of H3K4me3) [38]. We found that CTCF
binding sites and enhancers were more frequently found in the
vicinity of MLLr DMCs (+/2500 bp) than of IDH-mut DMCs
(Fisher’s exact test p-value: ,0.001 for both CTCF and enhancer
sites). Enhancers and CTCF binding sites were more frequently
hypomethylated in MLLr AMLs (Fisher’s exact test p-val-
ue,0.001), while in IDH-mut AMLs these sites were more
frequently hypermethylated (Fisher’s exact test p-value,0.001)
(Table 1). Whereas the mechanism through which IDH mutations
affect particular genes is unknown, MLL fusion proteins are known
to directly upregulate specific target genes, such as HOXA9, which
are essential for the transformation process [2]. To investigate this,
we surveyed the genomic localization of MLL fusions, MEIS1 or
HOXA9 by ChIP-seq and examined whether aberrant DNA
methylation was associated with binding of these factors. We found
that MLL bound more frequently at promoters, and that only 6.5%
of the 833MLL peaks covered by the ERRBS assay occurred within
500 bp of MLLr DMCs. While only 49 out of 614 of the HOXA9/
MEIS1 peaks [39] were covered by the ERRBS assay, 24.4% of
them were associated with DMCs in MLLr AMLs, the majority of
which were hypomethylated (22.4% vs 2%, Fisher’s exact test p-
value,0.004), suggesting that aberrant hypomethylation in MLLr
AMLs is more closely linked to the HOXA9 and its co-factor
MEIS1 than to the MLL fusion protein itself.
Context-dependent association of DNA methylation with
gene expression in AMLs
In order to determine the potential functional significance of the
distinct DNA methylation patterning observed in IDH-mut and
MLLr. (B) Horizontal barplot comparing the methylation status of CpG sites at DMCs in IDH-mut AML (top) and MLLr AML (bottom). Magenta depicts
.25% hypermethylation relative to NBM, green represents .25% hypomethylation and gray represents no differential methylation. Most DMCs are
non-overlapping between the two subtypes of AML and display opposite changes in methylation. However, amongst the smaller set of DMCs that do
overlap between the two AML subtypes, the vast majority (76.6%) are concordantly changed, with a clear predominance for aberrrant
hypermethylation of those sites (79%).
doi:10.1371/journal.pgen.1002781.g003
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MLLr AMLs we examined gene expression microarray profiles
from the same AML cases [10,40]. We assigned CpG sites into 3
types of regions: CpG islands overlapping a TSS, intergenic CpG
islands upstream of the TSS (up to 25 kb) and intragenic CpG
islands downstream of the TSS (up to +5 kb). Both in normal
CD34+ samples and leukemia specimens, hypomethylation within
CpG islands overlapping TSSs was associated with highly
expressed genes, while hypermethylation was observed for low
expression genes (top and bottom 15th percentile of expressed
transcripts, Wilcoxon rank sum test p-value,0.005) (Figure 6 and
Figure S6). However, the relationship between CpG shore
methylation status and gene expression levels was different in all
three sample types. Hypermethylation of CpG shores was
associated with low levels of gene expression only in MLLr AMLs,
both at CpG shores overlapping the TSS as well as at downstream
intragenic and upstream intergenic CpG shores. In marked
contrast, CpG shore methylation levels in IDH-mut AMLs
behaved in the opposite way, so that lower levels of methylation
were in fact associated with lower levels of expression (Wilcoxon
rank sum test p-value,0.005), while in normal CD34+ cases gene
expression levels did not appear to depend on CpG shore
methylation status at all.
Furthermore, when examining DMCs and their correlation
with differential gene expression between the different AMLs and
the normal bone marrow specimens, we found that only DMCs at
the core promoter regions were significantly inversely correlated
with differential gene expression in IDH-mut AMLs (p-val-
ue = 0.0047). However, for MLLr AMLs, we observed that while
core promoter DMCs were also significantly associated with
differential expression (p-value = 3.1e-16), this association was also
Figure 4. CpG islands and CpG shores show subtype-specific changes in the two types of AML. (A) Schematic representation of a CpG
island (light green), flanked upstream and downstream by 2 kb CpG shores (dark green) and the region that extends beyond CpG shores (black). (B)
Boxplots illustrating the magnitude of the methylation difference relative to NBM at DMCs that are annotated to CpG islands and CpG shores in either
IDH-mut (Left) or MLLr (right) AMLs. (C) Pie charts illustrating the relative proportion of DMCs annotated to CpG islands (light green), CpG shores
(dark green) and regions beyond CpG shores (black) in IDH-mut (left) and MLLr (right) AMLs.
doi:10.1371/journal.pgen.1002781.g004
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Figure 5. DMCs affect distinct genomic regions in IDH-mut and MLLr AMLs. (A) Top: cartoon representation of the different genomic
regions analyzed. Bottom: Pie charts illustrating the proportions of DMCs annotated to promoter regions (blue), exons (magenta), introns (orange)
and intergenic regions (black) in IDH-mut (left) and MLLr (right) AMLs. (B) Barplots representing the percentage of promoters, introns and exons
overlapping with a DMC in IDH-mut (left) and MLLr (right) AMLs. Significantly higher proportion of promoter regions were overlapping with a DMC in
IDH-mut over introns and exons, while introns were the most frequently affected regions in MLLr AMLs. (C) Histogram representing the log10
distance of DMCs to the nearest Transcription Start Site (TSS) in IDH-mut (red) and MLLr (blue) AMLs.
doi:10.1371/journal.pgen.1002781.g005
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significant at upstream DMCs (up to 10 kb), both for DMCs
located at CpG islands (p-value = 3.2e-11) and CpG shores (p-
value = 1.3e-23). Finally, downstream intronic DMCs overlapping
with CpG islands also showed a significant correlation with
expression in MLLr AMLs (p-value = 0.046). Collectively, these
findings suggest that subtype specific DNA methylation distribu-
tion in AMLs regulates gene expression in a subtype-defined
manner. More precisely our data indicate a significant role for
long-range epigenetic regulation in MLLr AML through distal
intergenic and intronic CpG islands, whereas IDH-mut AMLs
display a predominance of promoter-centric epigenetic regulatory
effects.
Discussion
The study of gene promoters and CpG islands under the
assumption that variation in the 5-methylcytosine status at these
locations would have functional importance has been the focus of
most cancer-related DNA methylation studies. Building upon the
previously described RRBS method, the ERRBS assay described
here made it possible to measure DNA methylation in primary
AML samples beyond promoter regions, extending even into distal
intergenic regions. This significantly enhanced genomic coverage
allowed us to demonstrate that heterogeneity in epigenomic
profiles in AML is not only a factor of different genes being
affected, but rather encompasses a far more complex scenario,
which includes the aberrant DNA methylation of distinct regions
of the genome as well as differential mechanisms of regulation of
gene expression according to genetic background. Given the
specificity and reproducibility of these aberrant DNA methylation
patterns, it is likely that their establishment in malignant cells is
directly linked to genetic driver lesions. Our previous studies using
HELP promoter microarrays are consistent with these results in
that they revealed a hypermethylated promoter signature in IDH-
mut AMLs, and a hypomethylated signature in MLLr. However
those studies did not have the resolution or depth to reveal the true
genomic nature, complexity and qualitative differences that we are
now able to report regarding the nature of cytosine methylation
distribution in these AML patients.
Specifically, in the case of MLLr leukemias, aberrant DNA
methylation consists mostly of aberrant hypomethylation of
upstream and intronic CpGs including CpG islands and shores,
but extending to and heavily involving even more distal regions.
Hypomethylation of regulatory elements is consistent with the
actions of MLL fusion proteins as transcriptional activators.
However, in these tumors the distal localization of hypomethyla-
tion was more closely associated with the presence of HOXA9 and
MEIS1 binding sites and enhancer regions than with MLL
binding sites, suggesting that aberrant DNA hypomethylation in
these tumors may be more closely related to effects of downstream
targets of MLL than to the fusion protein itself. However, it should
be noted that a subset of MLL peaks (6.5%) did indeed overlap
with DMCs in the MLLr AMLs. Since our ChIP-seq antibody
recognized both the wild-type and the rearranged copy of MLL.
Given that MLL fusions have been shown to bind to a subset of
wt-MLL target genes [41], it still remains possible that the subset
of overlapping peaks may be preferentially bound by the MLL
fusion. Further studies with antibodies capable of distinguishing
between the two forms of MLL will be required to properly
address the role of MLL fusions in helping establish the aberrant
methylation profile seen in these leukemias. The functional
relevance of hypomethylation in MLLs is supported by the
enrichment for highly transcribed genes at loci where this distal
methylation pattern is observed. IDH mutant AMLs on the other
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hand, display a diametrically opposed pattern of aberrant
methylation of CpGs, which results in the prefential hypermethy-
lation of CpG islands surrounding TSSs, involving an almost
entirely mutually exclusive set of CpGs but also resulting in the
downregulation of genes with increased methylation. While it is
clear that the generation of the 2-HG metabolite by the mutant
forms of IDH1 and IDH2 results in inhibition of the hydroxylation
reaction by TET proteins [6], it is as yet unclear why this
inhibition results in a promoter-specific hypermethylation pattern,
and inhibition of other epigenetic modifiers such as Jumonji C
domain histone demethylases by 2-HG [42] may also play a role in
determining the aberrant epigenetic profiles of these AMLs.
Figure 6. DNA methylation and gene expression relationships display subtype-specific differences. CpG islands and shores across the
genome were categorized into those located upstream from a transcription start site (TSS), overlapping a TSS or located downstream from a TSS.
Boxplots are plotted that illustrate the maximum DNA methylation levels at CpGs within these CpG islands and CpG shores for the top 15th
percentile expressed genes (right) and the bottom 15th percentile expressed genes (left). Each row shows a representative sample for each type:
Normal bone marrow (top); IDH-mut AML (middle) and MLLr AML (bottom). In all sample types CpG islands overlapping a TSS displayed lower
methylation levels in highly expressed genes and higher methylation levels in genes that were expressed at low levels. In MLLr AMLs this relationship
between expression and methylation levels further extended into CpG shores, and was also observed at CpG islands and shores upstream and
downstream from the TSS. IDH-mut AMLs, and to a lesser degree NBM samples, displayed higher methylation levels at CpG shores of genes with high
expression levels, while low methylation levels were observed at these shores for genes expressed at low levels.
doi:10.1371/journal.pgen.1002781.g006
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Moreover, it is possible that hydroxymethylation of DNA by TET
proteins may depend on other DNA binding partners that direct
them to specific genomic sites.
Even though the two AML subtypes were dramatically different,
they still shared a core hypermethylated signature including genes
previously shown to be almost universally hypermethylated in
AMLs [11]. Similar to what had been previously demonstrated in
colon cancer murine models [43,44], Broske and colleagues
demonstrated that DNA methylation is required to fully transform
hematopoietic stem and progenitors, even with a potent oncogene
such as MLL-AF9 [45]. Taken together, these observations point
towards the existence of a core of hypermethylation lesions that
are a necessary event during malignant transformation, and that
likely cooperate with the underlying genetic events in the different
AML subtypes.
Most importantly, abnormal DNA methylation patterning does
not occur in a stereotypical manner in cancer, but instead adopts
distinct and specific distributions dependent at least in part on
genetic background, even when comparing cases of the same
tumor type with different driver mutations. Our analysis
comparing gene expression and DNA methylation at base-pair
resolution across three different sample types demonstrates that
epigenetic regulation of gene expression in tumors may at least in
part be context dependent, suggesting that cell-type specific factors
may come into play to establish and maintain unique regulatory
mechanisms in these cells. Finally, the large distances between
DMCs and transcription start sites support a potential role for
epigenome regulation at distal regulatory elements, via looping or
other mechanisms, in directly influencing the specificity of the
transcriptional machinery. Taken together our data support the
existence of divergent roles of the epigenome in regulating the
transcriptional profiles of AML and indicate that altered gene
expression is associated with the differential methylation of distinct
and non-overlapping CpGs and regions in tumors with different
genetic backgrounds. Moreover, in the case of MLLr AMLs, these
abnormal regulatory mechanisms extend far beyond the classically
described cancer-associated promoter CpG island hypermethyla-
tion, and indicate that distal intergenic DNA methylation
abnormalities may also have functional consequences in certain
tumors. These findings are consistent with those described by
other groups which have seen an association between differentially
methylated regions at CpG shores in solid tumors and changes in
gene expression [13]. Indeed, these significant regional and CpG
specific differences would be unlikely to be captured with any
other method except whole genome bisulfite sequencing or
methods like ERRBS with unbiased and adequate base-pair
resolution detection of CpG methylation. Of note, the gene
expression microarrays used in the current study only capture
known coding transcripts. Yet the expanded coverage of ERRBS
can also provide information on putative regulatory elements of
non-coding RNAs as well as information on regulation of
alternative promoters. It will be important for future studies
perhaps using RNA-seq, to analyze the relationship between
aberrant DNA methylation and the expression levels of non-
coding RNAs or, the correlation between DNA methylation status
at alternative promoters and the expression levels of transcript
variants, a regulatory role previously described for DNA
methylation [46]. High resolution comparative studies of genet-
ically characterized primary human tumors using methods that
adequately represent the genome at base pair resolution (such as
RNA-Seq) may thus yield a wealth of new information on
mechanisms driving tumor transcriptional and epigenetic pro-
gramming and the true scope and nature of aberrant DNA
methylation patterning in cancer. Studies integrating more
comprehensive transcriptome data with transcription factor
binding and histone modification patterns in concert with assays
designed to explore chromosomal structure will yield further
insight into such mechanisms.
Methods
Cell lines
The human colorectal carcinoma cell line HCT116 was a kind
gift from Dr. John Mariadason. The cell line was maintained in
DMEM supplemented with 10% fetal bovine serum (FBS),
100 units/ml of penicillin and 100 mg/ml of streptomycin
(Invitrogen) at 37uC and 5% CO2. The HCT116 DNMT1(2/
2) DNMT3b(2/2) double knockout clone number 2 (DKO) cell
line was a kind gift from Dr. Steve Baylin. The cell line was grown
in McCoys’5A medium with 10% FBS, 0.2 mg/ml Neomy-
cin(G418), and 0.1 mg/ml Hygromycin B. Genomic DNA was
extracted from the cell lines using standard phenol:chloroform
extraction followed by ethanol precipitation.
Primary samples
AML samples were obtained from previously reported, de-
identified patient samples, from individuals enrolled in the Eastern
Cooperative Oncology Group’s (ECOG) E1900 clinical trial [47]
and from patients seen at Erasmus University MC, The Nether-
lands. Two IDH1/2 mutant AML samples (IDH1 and IDH2), two
mixed lineage leukemia gene rearranged AML samples harboring
t(9;11) (MLL1 and MLL2) and one additional AML sample (AML)
were available for processing. Two normal CD34+ bone marrow
control samples were purchased from AllCells, LLC (Emeryville,
CA, USA). Institutional review board approval was obtained at
Weill Cornell Medical Center and this study was performed in
accordance with the Helsinki protocols. DNA was isolated from
each primary sample using the Qiagen Puregene kit per
manufacturer’s recommendation.
Reduced representation bisulfite sequencing (RRBS)
RRBS was performed as follows: i) 5, 50 or 1000 ng of high
quality genomic DNA were digested with 200 U of MspI (New
England Biolabs, NEB) which cuts DNA regardless of cytosine
methylation status at CCGG sequence in a 100 ml reaction for up
to 16 hours at 37uC. DNA was isolated using standard phenol
chloroform extraction and ethanol precipitation and resuspended
into 30 ml of 10 mM TrIs pH 8.0.ii) End repair of digested DNA
was performed in a 100 ml reaction using 15 U of T4 DNA
polymerase (NEB M0203L), 5 U of Klenow DNA polymerase
(NEB M0210L), 50 U of T4 Polynucleotide Kinase (NEB
M0201L), 4 ml of premixed nucleotide triphosphates each at
10 mM (NEB N0447L) using T4 DNA ligase buffer with 10 mM
dATP (NEB B0202S). The reaction was incubated at 20uC for
30 minutes and products were isolated using QIAquick PCR
purification columns per manufacturer’s recommended protocol
(Qiagen) into 32 ml of EB buffer. iii) Adenylation was performed in
a 50 ml reaction using 15 U Klenow fragment (39 to 59 exo minus,
NEB M0212L), 10 ml of dATP at 1 mM concentration using
Klenow buffer (NEB). The reaction was incubated at 37uC for
30 minutes and products were isolated using MinElute PCR
purification columns per manufacturer’s recommended protocol
(Qiagen) into 10 ml EB buffer. iv) Adenylated DNA fragments
were ligated with pre-annealed 5-methylcytosine-containing Illu-
mina adapters in a 20 or 50 ml reaction for 5 ng or 50 ng or higher
starting materials respectively using 2000 U T4 DNA ligase (NEB
M0202T) and 1.2 mM final concentration of methylated adapters
at 16uC for a minimum of 16 hours. Products were isolated using
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MinElute columns per manufacturer’s recommended protocol
(Qiagen) into 10 ml EB buffer. v) Library fragments of 150–175
and 175–225 bp were gel isolated from a 1.5% agarose gel (using
low range ultra agarose from Biorad) using the Qiaquick Gel
Extraction kit per manufacturer’s recommended protocol (Qiagen)
into 40 ml EB buffer. vi) bisulfite treatment was performed using
the EZ DNA Methylation Kit (Zymo Research) per manufactur-
er’s recommended protocol with the following modifications: 1)
incubation after the addition of CT conversion reagent was
conducted in a thermocycler (Mastercycler ep gradient, Eppen-
dorf) with the following conditions: 30 seconds at 95uC followed
by 15 minutes at 50uC for 55 cycles and, 2) products were eluted
into 40 ml nuclease free water. vii) PCR amplification for each
library was performed in a 200 ml reaction containing 2 ml
FastStart Hifidelity DNA Polymerase (Roche), 0.5 mM each of
Illumina PCR primers PE1.0 and 2.0, 0.25 mM each nucleotide
triphosphate using buffer 2 per manufacturer’s recommendation
and divided into four 50 ml reactions. The thermocycler conditions
were: 5 minutes at 94uC, 18 cycles of 20 seconds at 94uC,
30 seconds at 65uC, 1 minutes at 72, followed by 3 minutes at
72uC. PCR products were isolated using AMPure XP beads per
manufacturer’s recommended protocol (Agencort) into 50 ml of
EB buffer. viii) All amplified libraries underwent quality control
steps including using Qubit 1.0 fluorometer and a Quant-iT
dsDNA HS Assay Kit for quantitation (Invitrogen) and bioana-
lyzer visualization (Agilent 2100 Bioanalyzer).
Extended Reduced Representation Bisulfite Sequencing
(ERRBS) was performed as described above for RRBS, except
that in step number v, library fragment lengths of 150–250 bp and
250–400 bp were gel isolated.
Data deposition statement. All data have been deposited
for public access in the GEO database. The Accession number is
GSE37454.
Sequencing
The amplified libraries were sequenced on an Illumina Genome
Analyzer II or HiSeq2000 per manufacturer’s recommended
protocol for 50 bp single end read runs. Image capture, analysis
and base calling was performed using Illumina’s CASAVA 1.7.
Quantitative DNA methylation sequencing by
MassARRAY EpiTYPER
Validation of select CpG methylation in HCT116 cell line was
implemented by MALDI-TOF mass spectrometry using EpiTY-
PER by MassARRAY (Sequenom, San Diego, CA) as previously
described [48]. Primers were designed to cover CpGs in various
chromosomal locations with various methylation levels and
sequencing coverage. Primers and amplicon sequences are listed
in Table S2.
Computational approaches
Bisulfite treated read alignment and methylation
calls. Reads were filtered from the adapter sequences using
FAR software (Dodt, M, Ahmed R, Dieterich C. FAR – flexible
adapter remover. FAR project website (2011) (http://sourceforge.
net/projects/theflexibleadap/). Adapter sequence contamination
usually occurs towards 39ends of some reads. The adapter
matching part of the read was removed if it aligned with the
adapter sequence at least 6 base-pairs and had at most 0.2
mismatch error rate. Reads were aligned to whole genome using
the bismark alignment software [24] with a maximum of 2
mismatches in a directional manner and only uniquely aligning
reads were retained. In order to call methylation score for a base
position, we required that read bases aligning to that position have
at least 20 phred quality score and the base position should have at
least 106 coverage. Only CpG dinucleotides that satisfy these
coverage and quality criteria were retained for subsequent
analysis. Percentage of bisulfite converted Cs (representing
unmethylated Cs) and non-converted Cs (representing methylated
Cs) were recorded for each C position in a CpG context.
Comparison of whole-genome alignment pipeline to MspI
fragment pipeline. In silico MspI fragment library was
constructed by cutting the reference genome to fragments from
MspI sites. Bisulfite converted reads are aligned to in silico bisulfite
converted MspI fragments using ELAND aligner. Similar to the
whole genome alignment pipeline, in order to call methylation
percentage score for a base position, we required that read bases
aligning to that position have at least 20 phred quality score and
the base position should have at least 106 coverage. We aligned
reads from 4 samples to MspI fragments and whole genome and
compared their alignment rate and number of covered CpGs.
CpG dinucleotide annotation. CpG islands, refseq genes
and repeat sequences were downloaded from the UCSC genome
browser [49]. CpG shores were defined as 2000 bp flanking
regions on upstream and downstream of a given CpG island [13].
If a 2000 bp shore overlapped with another island, then the shore
was clipped so that its last base falls before the start of the
overlapping CpG island. Similarly, if shores were overlapping they
were merged into a single shore. In addition, the genome was
partitioned to intergenic, intron, exon and promoter regions.
Promoter regions were defined as the 2 kb window centered on
the transcription start sites (TSS) of refseq genes. We classified
CpG dinucleotides as promoter, intronic, exonic or intergenic
based on their overlap with these predefined regions. In addition,
we classified CpG dinucleotides as CpG island or shore
overlapping.
Methylation comparison and differential methyla-
tion. Percent methylation values for CpG dinucleotides are
calculated by dividing number of methylated Cs by total coverage
on that base. We clustered samples and calculated methylation
correlations by comparing percent methylation scores of CpG
dinucleotides that are covered across all samples (IDH-mut, MLLr
and NBM samples).
Hierarchical clustering of the six samples was performed using
the hclust function in R-2.14.0 (http://www.r-project.org/) where
we used 1-Pearson correlation distance and Ward’s agglomeration
method.
Methylation values for genomic regions (intergenic, intron, exon
and promoters, CpG islands and island shores) between different
samples were compared by taking the mean methylation
percentage of CpG dinucleotides overlapping those regions. In
order to calculate the correlation between different samples and
generate the appropriate scatter plots we required that in any
given region at least 3 CpG dinucleotides were covered by reads in
both samples.
The test for differential methylation was performed at the single
base level. The test is performed only on CpG dinucleotides
covered in all the test and control samples in each case. In order to
improve the number of covered CpG dinucleotides across samples,
we merged the read coverage on forward and reverse strand of a
given CpG dinucleotide before doing the test. For the test, the
number of methylated and unmethylated Cs aligning to each base
were counted and compared across samples. To determine
significant differential methylation between two sets of samples,
we applied logistic regression and the likelihood ratio test.
Observed p-values were adjusted with the SLIM method [50]
We also calculated the percent methylation difference between the
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sets of test and control samples. We calculated the percent
methylation values per sample set by adding up the methylated C
counts for samples in the same set and dividing them by total read
coverage of two samples on that base. Consequently, we
subtracted these set specific percent methylation values from each
other to get percent methylation difference between the sample
sets.
Pathway enrichment analysis
Pathway enrichment analysis was performed using the GREAT
software [51], which associates genomic regions with nearby genes
and calculates enrichment statistics using annotations of those
genes. In order to associate genomic regions to genes, each gene is
assigned to a regulatory domain, which consists of a basal
promoter and extension around that promoter to cover distal
elements. Following that, the genomic regions falling on those
regulatory domains are associated with the genes. Following
parameters are used for definition of regulatory domain: 5000 bp
upstream, 1000 bp downstream of TSS as basal regulatory
domain and this is extended up to 100 kb maximum. GREAT
calculates two enrichment statistics using the binomial test and the
hypergeometric test. Only the pathways significant by both tests
are shown (FDR q-value,0.05).
Gene expression relationship with methylation
Gene expression for IDH mutants and normal bone marrow
cells are downloaded from the Gene Expression Omnibus (GEO)
(accession: GSE24505). Normal bone marrow samples are not
matched to the samples on this array however we averaged 5
normal bone marrow samples on the array to interpolate the
expression profiles of our normal bone marrow samples. The
sample matched gene expression profiles for cells with MLL
translocation are downloaded from GEO (accession: GSE6891).
Expression percentiles of each transcript are also calculated using
R function ‘‘ecdf’’. The transcripts for each sample are divided
into two categories high expressed (the top 15%) and low
expressed (the bottom 15%).
CpG islands are mapped to annotated transcripts for probes as
follows. First, we mapped CpG islands to 10 kb window around
the TSS of the annotated transcript, and CpG islands in this
window are classified as TSS overlapping, upstream and
downstream CpG islands depending on whether or not they
overlap with TSS and relative location if they are not overlapping
with TSS. Following that, we compared maximum methylation
per island and maximum methylation per shore for high and low
expressed genes on each sample. We used Wilcoxon’s Rank sum
test to compare maximum methylation distributions on each shore
and CpG island for high and low expressed genes. For this
comparison we only considered CpG islands and shores that have
at least three genomic CpGs covered by bisulfite reads.
When correlating DMCs with the differential expression, we
first calculated fold-change of MLLr vs. NBM and IDH-mut vs.
NBM samples. Expression data for NBM samples (although not
sample matched) were available for both IDH-mut and MLLr
fold-change calculations within the respective microarray types
and downloaded from GEO (accession numbers GSE24505 and
GSE6891 respectively). We calculated fold-change between the
average expression values of the groups. Following that we
measured correlation between percent methylation difference at
DMCs and fold-change of the nearest gene (obtained by extracting
the nearest TSS) using ‘‘correlation.test’’ in R. We performed
separate correlation analyses for DMCs at the core promoter
(2300 bp,+300 bp around TSS), upstream from the TSS (up to
10 kb), within CpG islands (up to 5 kb from TSS), within CpG
island shores (up to 5 kb from TSS), within intronic regions, at
intronic CpGs, and at CpGs within intronic CpG islands and
shores.
Chromatin immunoprecipiation–sequencing of MLL and
HOXA9
MLL ChIP-seq experiments were performed in the MLL-AF4
cell line RS4;11 (ATCC#CRL-1873) using antibodies to MLL1
(Bethyl Laboratories A300-086A). ChIP-seq libraries were pre-
pared from 10 ng of immunoprecipitated material using Illumina’s
ChIP-seq kit as per manufacturer’s instructions, and then
sequenced on a Genome Analyzer IIx sequencer. Alignment
against the human genome, peak calling and downstream analysis
was performed using ChIP-seeqer [52]. HoxA9 and Meis1 ChIP-
seq peaks from murine cells from Huang et al [39] were annotated
to the human genome using the LiftOver function from the UCSC
browser [49].
ChIP–seq peak overlap with DMCs
The ENCODE CTCF, H3K27me3, H3K4me1 and H3K4me3
peak locations are downloaded using UCSC table browser [53].
ChIP-seq experiments and peak finding were carried out by The
Broad Institute for 9 different cell lines only 8 of which had
H3K4me1 and H3K27me3 marks available for download [54].
Polycomb repressive marks were identified as those with
K3K27me3 by Ernst et al using a hidden-markov model based
approach [54]. For enhancer markers, we picked H3K4me1 sites
that do not overlap with H3K4me3 in a given a given cell line as
previously shown [38]. We merged all such H3K4me1 sites from 8
cell lines, so that if H3K4me1 sites overlap in different cell lines
they will not be counted twice. The same merging procedure is
applied for CTCF binding sites and H3K27me3 from 8 cell lines.
Following that, we extended the peak locations for CTCF,
enhancer markers, MLL, Meis1 and HoxA9 by 500 bp on each
side of the peak location. We overlapped resulting regions with
DMCs in IDH-mut and MLLr. We also overlapped those regions
with CpGs covered by reads to see how many of those binding
sites are covered by ERRBS. We applied Fisher’s exact test to
compare proportions of DMCs.
Supporting Information
Figure S1 ERRBS is highly reproducible and sensitive. (A)
Correlation between CpG dinucleotides, CpG islands and
promoter methylation levels using pearson correlation between
technical replicas of ERRBS using 5, 50 or 1000 ng genomic DNA
from the HCT116 cell line. (B) Distribution histograms of CpG
coverage and CpG methylation levels along forward and reverse
strands in HCT116 ERRBS results. (C) Distribution histogram of
CpG methylation levels along forward and reverse strands in
DKO ERRBS results. Similar results were obtained from reverse
strand (data not shown) and CpG coverage distributions over both
strands were similar to coverage seen with HCT116 sequencing
(data not shown). (D) Technical validation of ERRBS performance
in HCT116 at select CpGs by MassARRAY. Dot plot shows
correlation between DNA methylation as measured by ERRBS (x-
axis) and percent methylation as measured by MassARRAY
EpiTyper (y-axis). (Correlation coefficient: 0.97).
(TIF)
Figure S2 Biological replica reproducibility. (A) Correlation plot
of CpG dinucleotide methylation levels between two biological
replica of ERRBS data using normal bone marrow controls
(NBM_#1 and NBM_#2_Rep#2). (B) Correlation plot of CpG
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dinucleotide methylation levels between two biological replica of
ERRBS data using IDH mutant AML samples (IDH-mut_#1 and
IDH-mut_#2). (C) Correlation plot of CpG dinucleotide meth-
ylation levels between two biological replicas of ERRBS data using
MLL translocated AML samples (MLLr_#1_Rep#2 and
MLLr_#2).
(TIF)
Figure S3 DNA methylation patterns naturally segregate AML
and NBM samples. Unsupervised analysis using either principal
component analysis or hierarchical clustering (1-Pearson correla-
tion distance + Ward’s agglomerative algorithm) of DNA
methylation by ERRBS at (A) all CpGs, (B) non-promoter CpGs,
(C) non-promoter intron CpGs, (D) CpGs within CpG islands and
(E) CpGs within CpG shores, segregates the samples into their
three biological groups.
(TIF)
Figure S4 Differential methylation in MLLr and IDH-mut
AMLs are preserved at 40% and 10% cutoffs. Chromosome
ideogram representing differential methylation in IDH-mut AMLs
vs. NBM (A) and MLLr AMLs vs. NBM (B), using changes greater
than 10%. Light and dark magenta points represent hypermethy-
lation changes relative to NBM of 10–40% and greater than 40%
respectively. Light and dark green points represent hypomethyla-
tion changes relative to NBM of 10–40% and greater than 40%
respectively.
(TIF)
Figure S5 Percentage of DMCs overlapping with repeats. Bar
plots showing percentage of hyper- (magenta) and hypo-methyl-
ated (green) DMCs on repeat regions. Overall, 24–26% of hypo-
methylated DMCs and ,7% of hyper-methylated DMCs overlap
with repeats. 10.7% of hypo-methylated DMCs of MLLr overlap
with Alu repeats and 8.6% of hypo-methylated DMCs of IDH-
mut overlap with Alu repeats.
(TIF)
Figure S6 DNA methylation and gene expression relationships
display subtype-specific differences. CpG islands and shores across
the genome were categorized into those located upstream from a
transcription start site (TSS), overlapping a TSS or located
downstream from a TSS. Boxplots are plotted that illustrate the
maximum DNA methylation levels at these CpG islands and CpG
shores for the high expressed genes (top 15th percentile expressed
genes) and the low expressed genes (the bottom 15th percentile
expressed genes). Each row is for a different sample: Normal bone
marrow (top); IDH-mut AML (middle) and MLLr AML (bottom).
The boxplots are color-coded depending on the expression status
of associated genes. Significantly different distributions are marked
with a star.
(TIF)
Table S1 Summary of RRBS and ERRBS experiments. All
sequencing was performed using either the Illumina Genome
analyzer II or HiSeq2000 (50 base pair, single reads). We routinely
acquired .40 million reads per sample, with alignment rates
ranging from 55–70%. Shown are the number of CpGs covered,
bisulfite conversion efficiency and mean CpG coverage rates for
each sample.
(DOCX)
Table S2 Methylation sequencing by MassARRAY EpiTYPER.
MassARRAY was performed on bisulfite-converted DNA from
HCT116 using the following primers targeting the listed
amplicons.
(XLSX)
Table S3 Pathway analysis of DMCs in AML subtypes. Pathway
enrichment analysis was performed using GREAT. Enriched
terms in PANTHER Pathways are shown with their hyper-
geometric test and binomial test q-values. (A) Pathway analysis for
uniquely hyper-methylated DMCs in IDH-mut AML samples. (B)
Pathway analysis for uniquely hypo-methylated DMCs in MLL-r
AML samples. (See separate excel spreadsheet for full list of genes
in each pathway).
(XLSX)
Table S4 Pathway analysis of concordantly hypermethylated
DMCs in AML subtypes. Pathway enrichment analysis was
performed using GREAT. Enriched terms in PANTHER
Pathways are shown with their hyper-geometric test and binomial
test q-values. Results from pathway analysis for concordantly
hypermethylated DMCs in IDH-mut and MLL-r AML samples
are listed.
(DOCX)
Table S5 Genes with recurrent aberrant DNA methylation by
HELP that were validated by ERRBS. Listed are the fifteen (out of
a total of eighteen) genes covered by both assays that were
hypermethylated in the current study.
(DOCX)
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